View in EDS

LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.

Saved in:
Bibliographic Details
Title: LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Authors: Yeboah M; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Papagregoriou C; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Jones DC; Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom., Chan HTC; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Hu G; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., McPartlan JS; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Schiött T; BioInvent International AB, Lund, Sweden., Mattson U; BioInvent International AB, Lund, Sweden., Mockridge CI; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Tornberg UC; BioInvent International AB, Lund, Sweden., Hambe B; BioInvent International AB, Lund, Sweden., Ljungars A; BioInvent International AB, Lund, Sweden., Mattsson M; BioInvent International AB, Lund, Sweden., Tews I; Institute for Life Sciences and.; Biological Sciences, University of Southampton, Southampton, United Kingdom., Glennie MJ; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Thirdborough SM; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Trowsdale J; Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom., Frendeus B; BioInvent International AB, Lund, Sweden., Chen J; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Cragg MS; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom., Roghanian A; Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom.; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Source: JCI insight [JCI Insight] 2020 Sep 01; Vol. 5 (18). Date of Electronic Publication: 2020 Sep 01.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2379-3708
DOI:10.1172/jci.insight.141593